Eric Schmidhaeuser, managing director of Schorndorf operation, said: “We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our customers, both global and local. I am also pleased that this investment was made here in Schorndorf, as it builds upon our team’s commitment to operational excellence, our regulatory track record, and our consistent focus on meeting our customers’ needs.”
Catalent’s Schorndorf operation has been providing a range of services to global, regional and local pharmaceutical customers. The company also provides oral dose form development, manufacturing and packaging services, along with comprehensive supply chain solutions. In the fall of 2009, Catalent’s Schorndorf facility successfully completed an FDA inspection, including German and other EU and international regulatory authorities.